Recent Updates
Recently added Catalysts
ONC Positive Sentiment

BeOne Medicines to Present at the Jefferies Global Healthcare Conference

Key Takeaway: BeOne Medicines Ltd. announced its participation in the Jefferies Global Healthcare Conference on November 17, 2026. The event will feature a fireside chat at 9:30 a.m. GMT. The company is dedicated to developing innovative cancer treatments and has a diverse pipeline targeting hematology and solid tumors.

Market Sentiment Analysis

POSITIVE FACTORS

  • BeOne Medicines will present at a notable healthcare conference.
  • The company is focused on innovative cancer treatments.
  • BeOne has a diverse pipeline of novel therapeutics.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+45%
120-day peak, hindsight
Typical move
2.8%
average across 15 past catalysts
Lead asset
BGB-43395
Phase 1 · Advanced Solid Tumor

Full Press Release Details

SAN CARLOS, Calif.--(BUSINESS WIRE)--$ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, with a fireside chat at 9:30 a.m. GMT.
The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. An archived webcast will be available on the Company’s website.

About BeOne Medicines

BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before.
To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne’s plans, commitments, aspirations and goals related to BeOne’s medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled “Risk Factors” in BeOne’s most recent periodic report filed with the U.S. Securities and Exchange Commission (“SEC”) as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the SEC. All information in this press release is as of the date hereof, and BeOne undertakes no duty to update such information unless required by law.

Investor Contact: Liza Heapes Tel:+1 857-302-5663 ir@beonemed.com

Media Contact: Meredith Ferguson Tel:+1 216-338-3797 media@beonemed.com

Frequently Asked Questions

When will BeOne present at the Jefferies Conference?

BeOne Medicines will present on November 17, 2026.

What time is BeOne's presentation at the conference?

The presentation is scheduled for 9:30 a.m. GMT.

How can I access the live webcast?

The live webcast can be accessed from BeOne's investor section online.

What is BeOne Medicines focused on?

BeOne is focused on developing innovative treatments for cancer.

Last updated: Nov 3, 2026